This year’s definitive ranking of the biggest names in biotech investment
This report — the third in as many years — attempts to dig a little deeper into venture capital firms, to tease out not just which firms were best positioned before the downturn, but to look at which ones have made the best bets on the fledgling companies in which they invest — bets that have a big impact on the payouts for the venture capital firm and any of its investors.
By combing through data made available by Freedom of Information Act requests, STAT’s Kate Sheridan found otherwise private returns information for more than a dozen of the biggest names in biotech venture capital: Third Rock Ventures, OrbiMed, ARCH Venture Partners, and Flagship Pioneering.
The data reveal a stunning spectrum of performance: Some venture capital firms have quadrupled their investors’ money, while other funds have returned only the amount that was originally entrusted to them.
Get the report
About STAT Reports STAT Reports help business executives, researchers, consultants, and analysts navigate the ever-changing life sciences industry. Each report provides deep analysis of a particular issue in health care. Pick and purchase the reports that are most relevant to you. Learn More
Other topics include: | 
No comments